Halda Therapeutics has raised USD 126 million in an extended Series B funding round, with participation from new investors RA Capital Management, Deep Track Capital, Frazier Life Sciences, Vida Ventures, Boxer Capital, Taiho Ventures, and existing investors Canaan Partners, Connecticut Innovations, Access Biotechnology, and Elm Street Ventures.
The funds are expected to support the clinical trials of two regulated induced proximity targeting chimeras (RIPTAC) drug candidates targeting metastatic prostate and breast cancer. Halda’s lead therapeutic, HLD-0915, is expected to begin a Phase I trial in early 2025 for metastatic, castration-resistant prostate cancer (mCRPC). The funds will also support a second RIPTAC therapeutic for metastatic breast cancer and will help expand the company's team and product pipeline.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.